# Relay Therapeutics, Inc. (RLAY)

> Source: Nexqual · https://nexqual.com/RLAY · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Relay Therapeutics, Inc. (RLAY), nexqual.com/RLAY" · informational, not investment advice.

**Price:** USD 19.47 (-1.12% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 19.69 · day 19.31–20.2 · 52w 5.95–21.27 · market cap $4.27B · NGM

## Key facts
- Analysts: Buy (mean 1.77 on a 1–5 scale) (13 analysts), mean target USD 27.58 (range 20–32).
- Total return with dividends: 1Y +168.3% vs S&P 500 +14.8%; 5Y -41.4% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.4, revenue estimate $1.6M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: RLAY paid no cash dividend in the last five years.
- Short interest: 23.39% of float (as of 2026-10-15), 13.5 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 416.9x · P/B 4.8x · Earnings yield -6.63%

## Analysts
Consensus Buy (mean 1.77 on a 1–5 scale), 13 analysts; mean target USD 27.58 (low 20, high 32).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | HC Wainwright & Co. | Target raised | Buy | $28 → $29 |
| 2026-08-14 | JP Morgan | Target raised | Overweight | $28 → $31 |
| 2026-08-10 | Citizens | Target raised | Market Outperform | $21 → $26 |
| 2026-08-07 | Barclays | Target raised | Overweight | $27 → $30 |
| 2026-07-21 | Goldman Sachs | Target raised | Buy | $22 → $31 |
| 2026-07-16 | Canaccord Genuity | Initiated | Buy | $29 |
| 2026-07-08 | JP Morgan | Initiated | Overweight | $28 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +168.3% | -41.4% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +169.9% | -10.1% |
| Volatility (annualized) | 63.1% | 71.5% |
| Max drawdown | -28.1% (Apr 2026→May 2026) | -94.4% (Nov 2021→Mar 2025) |

## Dividends
RLAY paid no cash dividend in the last five years.

## Short interest
44,026,826 shares sold short, 23.39% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 44,487,428 shares (-1.0%). Days to cover: 13.5 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/RLAY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.40 | $-0.39 | −$0.01 | $1.6M | 11 |
| Next quarter (ends 2026-12-31) | $-0.38 | $-0.36 | −$0.02 | $7.8M | 11 |
| Current fiscal year (ends 2026-12-31) | $-1.61 | $-1.53 | −$0.09 | $11.2M | 11 |
| Next fiscal year (ends 2027-12-31) | $-1.63 | $-1.64 | +$0.01 | $17.9M | 11 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.41 | −$0.39 | Miss −5.1% | — |
| — | Quarter ended Mar 31, 2026 | −$0.41 | −$0.36 | Miss −13.9% | — |
| — | Quarter ended Dec 31, 2025 | −$0.31 | −$0.40 | Beat +22.5% | — |
| — | Quarter ended Sep 30, 2025 | −$0.43 | −$0.42 | Miss −2.4% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).